<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02978495</url>
  </required_header>
  <id_info>
    <org_study_id>BarretosCH - 20162</org_study_id>
    <nct_id>NCT02978495</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Carboplatin in Triple Negative Breast Cancer</brief_title>
  <official_title>Neoadjuvant Carboplatin in Triple Negative Breast Cancer - A Prospective Phase II Study (NACATRINE Trial).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barretos Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barretos Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer is the most frequent neoplasm in women in Brazil and in the world and up to 15%&#xD;
      of all cases diagnosed correspond to the triple negative subtype. Triple negative breast&#xD;
      cancer affects young women with germline mutations in BRCA 1/2 genes. Giving the lack of&#xD;
      target therapies to date, there is no consensus regarding the most effective treatment for&#xD;
      this subgroup of tumors. Although evidence shows that triple negative breast cancer is highly&#xD;
      sensitive to chemotherapy when compared to other breast tumors, there is no evidence to&#xD;
      support the hypothesis that patients with triple negative breast cancer and mutation in BRCA1&#xD;
      / 2 genes have higher chemosensitivity to neoadjuvant therapy. The investigator proposes a&#xD;
      prospective, randomized, open-label, phase II study, evaluating the rate of complete&#xD;
      pathologic response, disease-free survival, overall survival and prognostic evaluation of&#xD;
      BRCA1 / 2 mutation status in women with triple negative breast cancer submitted to sequential&#xD;
      neoadjuvant chemotherapy based on anthracycline and taxane, with or without carboplatin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 17, 2017</start_date>
  <completion_date type="Actual">October 22, 2021</completion_date>
  <primary_completion_date type="Actual">December 2, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response (pCR), defined as absence of invasive cancer in the breast and axillary lymph nodes.</measure>
    <time_frame>within the first 21 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>within the first 60 month after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>within the first 60 month after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>BRCA1 Hereditary Breast and Ovarian Cancer Syndrome</condition>
  <arm_group>
    <arm_group_label>A- BRCA Mutation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:&#xD;
Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B- BRCA Mutation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:&#xD;
Paclitaxel 80 mg/m2 once a week, for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C- BRCA wild-type</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:&#xD;
Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D- BRCA wild-type</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:&#xD;
Paclitaxel 80 mg/m2 once a week, for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorrubicin 60 mg/m2 4 cycles each 21 days</description>
    <arm_group_label>A- BRCA Mutation</arm_group_label>
    <arm_group_label>B- BRCA Mutation</arm_group_label>
    <arm_group_label>C- BRCA wild-type</arm_group_label>
    <arm_group_label>D- BRCA wild-type</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 1,5 once a week, for 12 weeks</description>
    <arm_group_label>A- BRCA Mutation</arm_group_label>
    <arm_group_label>C- BRCA wild-type</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>80mg/m2 weekly for 12 weeks</description>
    <arm_group_label>A- BRCA Mutation</arm_group_label>
    <arm_group_label>B- BRCA Mutation</arm_group_label>
    <arm_group_label>C- BRCA wild-type</arm_group_label>
    <arm_group_label>D- BRCA wild-type</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>600mg/m2 4 cycles each 21 days</description>
    <arm_group_label>A- BRCA Mutation</arm_group_label>
    <arm_group_label>B- BRCA Mutation</arm_group_label>
    <arm_group_label>C- BRCA wild-type</arm_group_label>
    <arm_group_label>D- BRCA wild-type</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Triple Negative Breast Cancer;&#xD;
&#xD;
          -  Stage II or III;&#xD;
&#xD;
          -  Performance Status ECOG &lt;2 or Karnofsky &gt;50%;&#xD;
&#xD;
          -  Hematologic (minimal values):&#xD;
&#xD;
        Absolute neutrophil count &gt; 1,500/mm3 Hemoglobin &gt; 10.0 g/dl Platelet count &gt; 100,000/mm3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage I or IV;&#xD;
&#xD;
          -  other malignancies.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Barretos Cancer Hospital</name>
      <address>
        <city>Barretos</city>
        <state>SP</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kummel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014 Jun;15(7):747-56. doi: 10.1016/S1470-2045(14)70160-3. Epub 2014 Apr 30.</citation>
    <PMID>24794243</PMID>
  </results_reference>
  <results_reference>
    <citation>Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Nekljudova V, Untch M, von Minckwitz G; German Breast Group Investigators. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol. 2013 Dec;24(12):2978-84. doi: 10.1093/annonc/mdt361. Epub 2013 Oct 17.</citation>
    <PMID>24136883</PMID>
  </results_reference>
  <results_reference>
    <citation>Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Dent R, Lubinski J, Narod S. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010 Jan 20;28(3):375-9. doi: 10.1200/JCO.2008.20.7019. Epub 2009 Dec 14.</citation>
    <PMID>20008645</PMID>
  </results_reference>
  <results_reference>
    <citation>Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4.</citation>
    <PMID>25092775</PMID>
  </results_reference>
  <results_reference>
    <citation>Valsecchi ME, Kimmey G, Bir A, Silbermins D. Role of Carboplatin in the Treatment of Triple Negative Early- Stage Breast Cancer. Rev Recent Clin Trials. 2015;10(2):101-10. doi: 10.2174/1574887110666150624101343.</citation>
    <PMID>26104428</PMID>
  </results_reference>
  <results_reference>
    <citation>Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011 Oct 1;29(28):3739-46. doi: 10.1200/JCO.2011.35.2682. Epub 2011 Sep 6.</citation>
    <PMID>21900106</PMID>
  </results_reference>
  <results_reference>
    <citation>Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011 Mar 1;17(5):1082-9. doi: 10.1158/1078-0432.CCR-10-2560. Epub 2011 Jan 13.</citation>
    <PMID>21233401</PMID>
  </results_reference>
  <results_reference>
    <citation>Paluch-Shimon S, Friedman E, Berger R, Papa M, Dadiani M, Friedman N, Shabtai M, Zippel D, Gutman M, Golan T, Yosepovich A, Catane R, Modiano T, Kaufman B. Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers. Breast Cancer Res Treat. 2016 May;157(1):157-65. doi: 10.1007/s10549-016-3800-5. Epub 2016 Apr 25.</citation>
    <PMID>27113739</PMID>
  </results_reference>
  <results_reference>
    <citation>Muendlein A, Rohde BH, Gasser K, Haid A, Rauch S, Kinz E, Drexel H, Hofmann W, Schindler V, Kapoor R, Decker T, Lang AH. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer. J Cancer Res Clin Oncol. 2015 Nov;141(11):2005-12. doi: 10.1007/s00432-015-1986-2. Epub 2015 May 15.</citation>
    <PMID>25971625</PMID>
  </results_reference>
  <verification_date>December 2022</verification_date>
  <study_first_submitted>November 24, 2016</study_first_submitted>
  <study_first_submitted_qc>November 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2016</study_first_posted>
  <last_update_submitted>December 25, 2022</last_update_submitted>
  <last_update_submitted_qc>December 25, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barretos Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Cristiano de Padua</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Hereditary Breast and Ovarian Cancer Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02978495
org study id: BarretosCH - 20162
nct id: NCT02978495
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
is us export: No
Breast cancer is the most frequent neoplasm in women in Brazil and in the world and up to 15%
      of all cases diagnosed correspond to the triple negative subtype. Triple negative breast
      cancer affects young women with germline mutations in BRCA 1/2 genes. Giving the lack of
      target therapies to date, there is no consensus regarding the most effective treatment for
      this subgroup of tumors. Although evidence shows that triple negative breast cancer is highly
      sensitive to chemotherapy when compared to other breast tumors, there is no evidence to
      support the hypothesis that patients with triple negative breast cancer and mutation in BRCA1
      / 2 genes have higher chemosensitivity to neoadjuvant therapy. The investigator proposes a
      prospective, randomized, open-label, phase II study, evaluating the rate of complete
      pathologic response, disease-free survival, overall survival and prognostic evaluation of
      BRCA1 / 2 mutation status in women with triple negative breast cancer submitted to sequential
      neoadjuvant chemotherapy based on anthracycline and taxane, with or without carboplatin.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Pathological complete response (pCR), defined as absence of invasive cancer in the breast and axillary lymph nodes.
time frame: within the first 21 days after surgery
measure: Disease free survival (DFS)
time frame: within the first 60 month after surgery
measure: Overall survival (OS)
time frame: within the first 60 month after surgery
arm group label: A- BRCA Mutation
arm group type: Experimental
description: Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:
Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks.
arm group label: B- BRCA Mutation
arm group type: Active Comparator
description: Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:
Paclitaxel 80 mg/m2 once a week, for 12 weeks.
arm group label: C- BRCA wild-type
arm group type: Experimental
description: Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:
Paclitaxel 80 mg/m2 once a week, for 12 weeks, concomitant to Carboplatin AUC 1,5 once a week, for 12 weeks.
arm group label: D- BRCA wild-type
arm group type: Active Comparator
description: Doxorrubicin 60 mg/m2 concomitantly with Cyclophosphamide 600mg/m2, every 3 weeks, for 4 cycles followed by:
Paclitaxel 80 mg/m2 once a week, for 12 weeks.
intervention type: Drug
intervention name: Doxorubicin
description: Doxorrubicin 60 mg/m2 4 cycles each 21 days
arm group label: A- BRCA Mutation
arm group label: B- BRCA Mutation
arm group label: C- BRCA wild-type
arm group label: D- BRCA wild-type
intervention type: Drug
intervention name: Carboplatin
description: Carboplatin AUC 1,5 once a week, for 12 weeks
arm group label: A- BRCA Mutation
arm group label: C- BRCA wild-type
intervention type: Drug
intervention name: Paclitaxel
description: 80mg/m2 weekly for 12 weeks
arm group label: A- BRCA Mutation
arm group label: B- BRCA Mutation
arm group label: C- BRCA wild-type
arm group label: D- BRCA wild-type
intervention type: Drug
intervention name: Cyclophosphamide
description: 600mg/m2 4 cycles each 21 days
arm group label: A- BRCA Mutation
arm group label: B- BRCA Mutation
arm group label: C- BRCA wild-type
arm group label: D- BRCA wild-type
criteria: 
gender: Female
minimum age: 18 Years
maximum age: N/A
healthy volunteers: Accepts Healthy Volunteers
facility: 
country: Brazil
citation: von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kummel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014 Jun;15(7):747-56. doi: 10.1016/S1470-2045(14)70160-3. Epub 2014 Apr 30.
PMID: 24794243
citation: Gerber B, Loibl S, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Nekljudova V, Untch M, von Minckwitz G; German Breast Group Investigators. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol. 2013 Dec;24(12):2978-84. doi: 10.1093/annonc/mdt361. Epub 2013 Oct 17.
PMID: 24136883
citation: Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Dent R, Lubinski J, Narod S. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010 Jan 20;28(3):375-9. doi: 10.1200/JCO.2008.20.7019. Epub 2009 Dec 14.
PMID: 20008645
citation: Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014 Aug 4.
PMID: 25092775
citation: Valsecchi ME, Kimmey G, Bir A, Silbermins D. Role of Carboplatin in the Treatment of Triple Negative Early- Stage Breast Cancer. Rev Recent Clin Trials. 2015;10(2):101-10. doi: 10.2174/1574887110666150624101343.
PMID: 26104428
citation: Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011 Oct 1;29(28):3739-46. doi: 10.1200/JCO.2011.35.2682. Epub 2011 Sep 6.
PMID: 21900106
citation: Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011 Mar 1;17(5):1082-9. doi: 10.1158/1078-0432.CCR-10-2560. Epub 2011 Jan 13.
PMID: 21233401
citation: Paluch-Shimon S, Friedman E, Berger R, Papa M, Dadiani M, Friedman N, Shabtai M, Zippel D, Gutman M, Golan T, Yosepovich A, Catane R, Modiano T, Kaufman B. Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers. Breast Cancer Res Treat. 2016 May;157(1):157-65. doi: 10.1007/s10549-016-3800-5. Epub 2016 Apr 25.
PMID: 27113739
citation: Muendlein A, Rohde BH, Gasser K, Haid A, Rauch S, Kinz E, Drexel H, Hofmann W, Schindler V, Kapoor R, Decker T, Lang AH. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer. J Cancer Res Clin Oncol. 2015 Nov;141(11):2005-12. doi: 10.1007/s00432-015-1986-2. Epub 2015 May 15.
PMID: 25971625
responsible party type: Principal Investigator
investigator affiliation: Barretos Cancer Hospital
investigator full name: Cristiano de Padua
investigator title: Principal Investigator
mesh term: Triple Negative Breast Neoplasms
mesh term: Hereditary Breast and Ovarian Cancer Syndrome
mesh term: Paclitaxel
mesh term: Cyclophosphamide
mesh term: Carboplatin
mesh term: Doxorubicin
sharing ipd: Undecided